Literature DB >> 33426808

MYC promotes cancer progression by modulating m6 A modifications to suppress target gene translation.

Gongwei Wu1,2, Caixia Suo1,3, Ying Yang4, Shengqi Shen2, Linchong Sun1,3, Shi-Ting Li2, Yingli Zhou2, Dongdong Yang2, Yan Wang2, Yongping Cai5, Nana Wang5, Huafeng Zhang2, Yun-Gui Yang4,6,7,8, Jie Cao1,3, Ping Gao1,2,3,9.   

Abstract

The MYC oncoprotein activates and represses gene expression in a transcription-dependent or transcription-independent manner. Modification of mRNA emerges as a key gene expression regulatory nexus. We sought to determine whether MYC alters mRNA modifications and report here that MYC promotes cancer progression by down-regulating N6-methyladenosine (m6 A) preferentially in transcripts of a subset of MYC-repressed genes (MRGs). We find that MYC activates the expression of ALKBH5 and reduces m6 A levels in the mRNA of the selected MRGs SPI1 and PHF12. We also show that MYC-regulated m6 A controls the translation of MRG mRNA via the specific m6 A reader YTHDF3. Finally, we find that inhibition of ALKBH5, or overexpression of SPI1 or PHF12, effectively suppresses the growth of MYC-deregulated B-cell lymphomas, both in vitro and in vivo. Our findings uncover a novel mechanism by which MYC suppresses gene expression by altering m6 A modifications in selected MRG transcripts promotes cancer progression.
© 2021 The Authors.

Entities:  

Keywords:  ALKBH5; MYC; MYC-repressed genes; m6A; oncogenesis

Mesh:

Substances:

Year:  2021        PMID: 33426808      PMCID: PMC7926262          DOI: 10.15252/embr.202051519

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  56 in total

1.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.

Authors:  Zejuan Li; Hengyou Weng; Rui Su; Xiaocheng Weng; Zhixiang Zuo; Chenying Li; Huilin Huang; Sigrid Nachtergaele; Lei Dong; Chao Hu; Xi Qin; Lichun Tang; Yungui Wang; Gia-Ming Hong; Hao Huang; Xiao Wang; Ping Chen; Sandeep Gurbuxani; Stephen Arnovitz; Yuanyuan Li; Shenglai Li; Jennifer Strong; Mary Beth Neilly; Richard A Larson; Xi Jiang; Pumin Zhang; Jie Jin; Chuan He; Jianjun Chen
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

Review 2.  The Critical Role of RNA m6A Methylation in Cancer.

Authors:  Qing Lan; Pei Y Liu; Jacob Haase; Jessica L Bell; Stefan Hüttelmaier; Tao Liu
Journal:  Cancer Res       Date:  2019-03-20       Impact factor: 12.701

Review 3.  Rethinking m6A Readers, Writers, and Erasers.

Authors:  Kate D Meyer; Samie R Jaffrey
Journal:  Annu Rev Cell Dev Biol       Date:  2017-07-31       Impact factor: 13.827

4.  c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

Authors:  Zuqin Nie; Gangqing Hu; Gang Wei; Kairong Cui; Arito Yamane; Wolfgang Resch; Ruoning Wang; Douglas R Green; Lino Tessarollo; Rafael Casellas; Keji Zhao; David Levens
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

5.  Control of cell growth by c-Myc in the absence of cell division.

Authors:  M Schuhmacher; M S Staege; A Pajic; A Polack; U H Weidle; G W Bornkamm; D Eick; F Kohlhuber
Journal:  Curr Biol       Date:  1999-11-04       Impact factor: 10.834

6.  Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis.

Authors:  Shi-Ting Li; Shengqi Shen; Yongping Cai; Songge Xing; Gongwei Wu; Zetan Jiang; Yijie Hao; Mengqiu Yuan; Nana Wang; Lianbang Zhu; Ronghui Yan; Dongdong Yang; Lin Wang; Zhaoji Liu; Xin Hu; Rongbin Zhou; Kun Qu; Ailing Li; Xiaotao Duan; Huafeng Zhang; Ping Gao
Journal:  Nat Metab       Date:  2020-03-16

7.  A large scale genetic analysis of c-Myc-regulated gene expression patterns.

Authors:  Brenda C O'Connell; Ann F Cheung; Carl P Simkevich; Wanny Tam; Xiaojia Ren; Maria K Mateyak; John M Sedivy
Journal:  J Biol Chem       Date:  2003-01-14       Impact factor: 5.157

Review 8.  The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis.

Authors:  Patrick A Carroll; Brian W Freie; Haritha Mathsyaraja; Robert N Eisenman
Journal:  Front Med       Date:  2018-07-27       Impact factor: 4.592

9.  c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.

Authors:  Kamini Singh; Jianan Lin; Yi Zhong; Antonija Burčul; Prathibha Mohan; Man Jiang; Liping Sun; Vladimir Yong-Gonzalez; Agnes Viale; Justin R Cross; Ronald C Hendrickson; Gunnar Rätsch; Zhengqing Ouyang; Hans-Guido Wendel
Journal:  J Exp Med       Date:  2019-05-29       Impact factor: 14.307

10.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Authors:  Rui Su; Lei Dong; Chenying Li; Sigrid Nachtergaele; Mark Wunderlich; Ying Qing; Xiaolan Deng; Yungui Wang; Xiaocheng Weng; Chao Hu; Mengxia Yu; Jennifer Skibbe; Qing Dai; Dongling Zou; Tong Wu; Kangkang Yu; Hengyou Weng; Huilin Huang; Kyle Ferchen; Xi Qin; Bin Zhang; Jun Qi; Atsuo T Sasaki; David R Plas; James E Bradner; Minjie Wei; Guido Marcucci; Xi Jiang; James C Mulloy; Jie Jin; Chuan He; Jianjun Chen
Journal:  Cell       Date:  2017-12-14       Impact factor: 66.850

View more
  13 in total

Review 1.  Crosstalk between m6A regulators and mRNA during cancer progression.

Authors:  Xiaodong Niu; Yuan Yang; Yanming Ren; Shengtao Zhou; Qing Mao; Yuan Wang
Journal:  Oncogene       Date:  2022-08-25       Impact factor: 8.756

Review 2.  RNA N6-Methyladenine Modification, Cellular Reprogramming, and Cancer Stemness.

Authors:  Huarong Chen; Yifei Wang; Hao Su; Xiaoting Zhang; Hongyan Chen; Jun Yu
Journal:  Front Cell Dev Biol       Date:  2022-07-04

3.  Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy.

Authors:  Yuzhen Gao; Hao Wang; Shipeng Chen; Rui An; Yadong Chu; Guoli Li; Yanzhong Wang; Xinyou Xie; Jun Zhang
Journal:  J Transl Med       Date:  2022-05-04       Impact factor: 8.440

4.  MYC promotes cancer progression by modulating m6 A modifications to suppress target gene translation.

Authors:  Gongwei Wu; Caixia Suo; Ying Yang; Shengqi Shen; Linchong Sun; Shi-Ting Li; Yingli Zhou; Dongdong Yang; Yan Wang; Yongping Cai; Nana Wang; Huafeng Zhang; Yun-Gui Yang; Jie Cao; Ping Gao
Journal:  EMBO Rep       Date:  2021-01-11       Impact factor: 8.807

Review 5.  Research progress on epigenetics of small B-cell lymphoma.

Authors:  Xueqin Ruan; Rong Zhang; Hongkai Zhu; Can Ye; Zhihua Wang; En Dong; Ruijuan Li; Zhao Cheng; Hongling Peng
Journal:  Clin Transl Oncol       Date:  2022-03-25       Impact factor: 3.340

6.  Construction of circRNA-Based ceRNA Network to Reveal the Role of circRNAs in the Progression and Prognosis of Hepatocellular Carcinoma.

Authors:  Rong Deng; Xiaohan Cui; Yuxiang Dong; Yanqiu Tang; Xuewen Tao; Shuyu Wang; Jincheng Wang; Lin Chen
Journal:  Front Genet       Date:  2021-02-26       Impact factor: 4.599

7.  Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.

Authors:  Jiannan Yao; Ling Duan; Xuying Huang; Jian Liu; Xiaona Fan; Zeru Xiao; Rui Yan; Heshu Liu; Guangyu An; Bin Hu; Yang Ge
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

8.  SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner.

Authors:  Shouji Zhang; Shulin Zhao; Yanhua Qi; Boyan Li; Huizhi Wang; Ziwen Pan; Hao Xue; Chuandi Jin; Wei Qiu; Zihang Chen; Qindong Guo; Yang Fan; Jianye Xu; Zijie Gao; Shaobo Wang; Xing Guo; Lin Deng; Shilei Ni; Fuzhong Xue; Jian Wang; Rongrong Zhao; Gang Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-01       Impact factor: 8.886

Review 9.  Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug.

Authors:  Wen-Min Zhou; Bin Liu; Amin Shavandi; Lu Li; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

Review 10.  The Role of N6-Methyladenosine (m6A) Methylation Modifications in Hematological Malignancies.

Authors:  Yan Zhao; Hongling Peng
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.